Skip Navigation



Annals of Oncology Advance Access published online on August 26, 2005
Annals of Oncology, doi:10.1093/annonc/mdi397
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/12/1915    most recent
mdi397v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Maroto, P.
Right arrow Articles by Germà-Lluch, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maroto, P.
Right arrow Articles by Germà-Lluch, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received March 23, 2005
Revised July 13, 2005
Accepted July 20, 2005

Original article

Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours

P. Maroto 1*, X. García del Muro 1, J. Aparicio 1, L. Paz-Ares 1, J. A. Arranz 1, J. Guma 1, J. Terrassa 1, J. Barnadas 1, J. Dorta 1, and J. R. Germà-Lluch 1

1 The Spanish Germinal Group, Spain

* To whom correspondence should be addressed.
P. Maroto, E-mail: jmaroto{at}hsp.santpau.es


  Abstract

Background: The Spanish Germ Cell Group is composed of 60 centres. Our challenge was to define a surveillance protocol that would be safe and suitable regardless of population size or geographic coverage.

Methods: From January 1994 to January 2004, 589 patients with stage I non-seminomatous germ cell tumours entered a risk-adapted surveillance protocol after orchiectomy. Patients with vascular or local invasion of adjacent structures (231/589; 39%) received two cycles of BE400P (bleomicin 30 U/week, etoposide 100 mg/m2 x4, cisplatinum 25 mg/m2 x4). Other patients (358/589; 61%) were kept on close follow-up (chest X-ray; serum tumour markers: first year every 2 months, second year every 3 months, third year every 4 months; abdominal computed tomography scans at every other outpatient control). The outcomes selected for the study were feasibility, relapse rate and number of patients lost to follow-up and mortality.

Results: Median follow-up was 40 months. In the surveillance group, 21 patients were lost to follow-up. In the chemotherapy group, two patients relapsed at 12 and 14.5 months and they are presently free of disease. In the surveillance group, 71 (19%) patients relapsed, of which 55 (71%) relapsed within the first year. Five (1.4%) patients died of their cancer. Factors associated with relapse were embryonal carcinoma and vascular invasion in patients who refused chemotherapy.

Conclusions: Our risk-adapted surveillance protocol provided a low rate of recurrences.

Keywords: non-seminomatous germ cell tumours; stage I; risk-adapted surveillance.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
C. Kollmannsberger, C. Moore, K. N. Chi, N. Murray, S. Daneshmand, M. Gleave, B. Hayes-Lattin, and C.R. Nichols
Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy
Ann. Onc., October 29, 2009; (2009) mdp473v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Albers, R. Siener, S. Krege, H.-U. Schmelz, K.-P. Dieckmann, A. Heidenreich, P. Kwasny, M. Pechoel, J. Lehmann, S. Kliesch, et al.
Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group
J. Clin. Oncol., June 20, 2008; 26(18): 2966 - 2972.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Oldenburg, J. M. Martin, and S. D. Fossa
Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis
J. Clin. Oncol., December 10, 2006; 24(35): 5503 - 5511.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.